Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

NCT03493685 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

371

Enrollment

INDUSTRY

Sponsor class

Conditions

Focal Segmental Glomerulosclerosis

Interventions

DRUG: sparsentan
DRUG: Irbesartan

Sponsor

Travere Therapeutics, Inc.